Mocon (MOCO) 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'MOCON INC	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	5,673,293
Amendment Flag	'false	'
Entity Central Index Key	'0000067279	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Accelerated Filer	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$6,140,566	$4,132,953
Marketable securities, current	'	205,000
Trade accounts receivable, less allowance for doubtful accounts of $203,559 in 2014 and $315,417 in 2013	10,461,565	12,335,124
Other receivables	225,930	273,405
Inventories	8,551,490	7,470,697
Prepaid income taxes	239,610	595,898
Prepaid expenses, other	1,135,754	1,126,582
Deferred income taxes	1,176,862	1,429,794
Total current assets	27,931,777	27,569,453
Property, plant and equipment, net of accumulated depreciation of $8,206,401 in 2014 and $7,811,276 in 2013	5,734,893	5,726,754
Goodwill	8,443,000	9,034,479
Investment in affiliated company	3,171,250	3,441,500
Intangible assets, net	11,341,704	12,718,203
Other assets	196,805	213,279
TOTAL ASSETS	56,819,429	58,703,668
Current liabilities:	'	'
Current maturities of notes payable	1,819,312	2,697,678
Revolving lines of credit	4,500,000	4,263,821
Accounts payable	3,635,323	3,864,355
Compensation and related expenses	3,538,071	3,752,542
Other accrued expenses	952,680	781,151
Accrued product warranties	240,575	335,533
Dividends payable	624,062	619,322
Deferred revenue	1,176,187	620,428
Total current liabilities	16,486,210	16,934,830
Notes payable	541,033	1,306,849
Obligations to former employees	71,261	77,334
Deferred income taxes	1,904,446	2,611,491
Accrued income taxes	295,353	304,424
Total noncurrent liabilities	2,812,093	4,300,098
Total liabilities	19,298,303	21,234,928
Capital stock – undesignated. Authorized 3,000,000 shares; none issued and outstanding in 2014 and 2013	'	'
Common stock – $0.10 par value. Authorized 22,000,000 shares; issued and outstanding 5,673,293 shares in 2014 and 5,630,197 shares in 2013	567,329	563,020
Additional paid-in capital	5,773,400	5,063,627
Retained earnings	32,928,040	31,229,068
Accumulated other comprehensive (loss) income	-1,747,643	613,025
Total stockholders' equity	37,521,126	37,468,740
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$56,819,429	$58,703,668

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Trade accounts receivable, allowance for doubtful accounts (in Dollars)	$203,559	$315,417
Property, plant and equipment, accumulated depreciation (in Dollars)	$8,206,401	$7,811,276
Capital stock, authorized shares	3,000,000	3,000,000
Capital stock, shares issued	0	0
Capital stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$0.10	$0.10
Common stock, authorized	22,000,000	22,000,000
Common stock, shares issued	5,673,293	5,630,197
Common stock, shares outstanding	5,673,293	5,630,197

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Income (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Sales:	'	'	'	'
Products	$15,855,843	$13,400,132	$45,366,872	$40,088,427
Consulting services	793,784	789,741	2,170,426	2,236,639
Total sales	16,649,627	14,189,873	47,537,298	42,325,066
Cost of sales:	'	'	'	'
Products	6,640,087	5,657,331	19,451,207	17,275,469
Consulting services	447,219	473,621	1,412,616	1,356,904
Total cost of sales	7,087,306	6,130,952	20,863,823	18,632,373
Gross profit	9,562,321	8,058,921	26,673,475	23,692,693
Selling, general and administrative expenses	6,125,438	5,257,664	18,215,810	16,528,574
Research and development expenses	949,678	886,289	3,063,955	3,084,583
Operating income	2,487,205	1,914,968	5,393,710	4,079,536
Other expense, net	-116,923	-95,308	-267,105	-285,990
Income before income taxes	2,370,282	1,819,660	5,126,605	3,793,546
Income tax expense	696,456	460,999	1,557,803	766,637
Net income	$1,673,826	$1,358,661	$3,568,802	$3,026,909
Net income per common share:	'	'	'	'
Basic (in Dollars per share)	$0.30	$0.24	$0.63	$0.55
Diluted (in Dollars per share)	$0.29	$0.24	$0.62	$0.53
Weighted average common shares outstanding:	'	'	'	'
Basic (in Shares)	5,667,810	5,548,201	5,654,620	5,535,687
Diluted (in Shares)	5,775,767	5,684,515	5,767,984	5,673,694
Cash dividends declared per common share (in Dollars per share)	$0.11	$0.11	$0.33	$0.33

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net income	$1,673,826	$1,358,661	$3,568,802	$3,026,909
Other comprehensive income (loss):	'	'	'	'
Cumulative translation adjustment	-2,106,847	1,058,066	-2,360,668	651,609
Comprehensive income (loss)	($433,021)	$2,416,727	$1,208,134	$3,678,518

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net income	$3,568,802	$3,026,909
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Stock-based compensation expense	413,447	390,269
Change in fair value of derivative instrument	172,278	-8,041
(Gain)/Loss on disposition of long-term assets	16,341	-44,889
Depreciation and amortization	1,923,936	1,795,379
Deferred income taxes	-308,889	-696,569
Excess tax benefit from employee stock plans	-16,067	-19,670
Changes in operating assets and liabilities:	'	'
Trade accounts receivable, net	842,995	-589,435
Other receivables	-130,329	47,421
Inventories	-1,339,741	-603,719
Prepaid income taxes	47,440	-66,391
Prepaid expenses, other	32,944	-231,019
Accounts payable	252,873	758,978
Compensation and related expenses	-61,286	-227,579
Other accrued expenses	76,972	-4,666
Accrued product warranties	-85,395	-1,738
Accrued income taxes	435,550	503,719
Deferred revenue	588,028	385,608
Net cash provided by operating activities	6,429,899	4,414,567
Cash flows from investing activities:	'	'
Proceeds from maturities of marketable securities	205,000	5,254,639
Purchases of property, plant and equipment	-998,706	-1,308,243
Proceeds from sale of property and equipment	55,315	116,234
Cash paid for patents and other intangible assets	-372,504	-669,154
Other	-2,230	-2,259
Net cash provided by (used in) investing activities	-1,113,125	3,391,217
Cash flows from financing activities:	'	'
Proceeds from the revolving lines of credit	18,383,528	4,757,484
Payments on the revolving lines of credit	-18,143,489	-7,532,789
Payments on notes payable and seller financed note payable	-1,641,199	-1,453,660
Proceeds from the exercise of stock options	284,568	256,212
Excess tax benefit from employee stock plans	16,067	19,670
Dividends paid	-1,865,089	-1,798,208
Net cash used in financing activities	-2,965,614	-5,751,291
Effect of exchange rate changes on cash and cash equivalents	-343,547	24,407
Net increase in cash and cash equivalents	2,007,613	2,078,900
Cash and cash equivalents:	'	'
Beginning of period	4,132,953	2,415,416
End of period	6,140,566	4,494,316
Supplemental disclosures of cash flow information:	'	'
Cash paid during the period for income taxes	1,067,365	1,166,483
Cash paid during the period for interest	151,949	221,299
Supplemental schedule of noncash investing and financing activities:	'	'
Dividends accrued	624,062	610,404
Purchases of prepaid expenses, fixed assets and intangibles in accounts payable	$173,665	$217,344

Note_1_Condensed_Consolidated_

Note 1 - Condensed Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	'
	Note 1 – Condensed Consolidated Financial Statements
	The condensed consolidated balance sheets as of September 30, 2014, the condensed consolidated statements of income and comprehensive income (loss), for the three and nine-month periods ended September 30, 2014 and 2013 and the condensed consolidated statements of cash flows for the nine-month period ended September 30, 2014 and 2013 have been prepared in accordance with accounting principles generally accepted in the United States of America. These interim unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to fairly present the financial position, results of operations and cash flows at September 30, 2014, and for all periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.
	The results of operations for the three and nine-month periods ended September 30, 2014 are not necessarily indicative of operating results for the full year. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2013, previously filed with the Securities and Exchange Commission.
	MOCON Inc. and its subsidiaries (collectively, the Company), develops, manufacturers and markets measurement, analytical and monitoring instruments, and provides consulting services for customers in the barrier packaging, food, pharmaceutical, consumer products, industrial hygiene, environmental, air quality monitoring, oil and gas exploration and other industries throughout the world.
	We report our operating segments as Permeation Products and Services (“Permeation”), Package Testing Products and Services (“Package Testing”), and Industrial Analyzer Products and Services and Other (“Industrial Analyzers and Other”) for financial reporting purposes.
	Principles of Consolidation
	The condensed consolidated financial statements include the accounts of MOCON, Inc. and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
	Recently Issued Accounting Guidance
	Revenue from Contracts with Customers
	In May 2014, the Financial Accounting Standards Board issued new accounting requirements for the recognition of revenue from contracts with customers. The requirements of the new standard are effective for annual reporting periods beginning after December 15, 2016, and interim periods within those annual periods. We are currently evaluating the impact of this guidance on our results of operations and financial position.

Note_2_Inventories

Note 2 - Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 2 – Inventories
	Inventories consist of the following:
		September 30,		December 31,
		2014		2013
	Finished products	$	1,730,912	$	1,638,997
	Work-in-process		2,645,502		1,934,493
	Raw materials		4,175,076		3,897,207
		$	8,551,490	$	7,470,697

Note_3_Net_Income_Per_Common_S

Note 3 - Net Income Per Common Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 3 – Net Income Per Common Share
	Basic net income per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted net income per common share is computed using the treasury stock method to compute the weighted average common stock outstanding assuming the conversion of potential dilutive common shares.
	The following table presents a reconciliation of the denominators used in the computation of net income per common share – basic, and net income per common share – diluted, for the three and nine-month periods ended September 30, 2014 and 2013:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Weighted shares of common stock outstanding – basic		5,667,810		5,548,201		5,654,620		5,535,687
	Dilutive impact of share-based awards		107,957		136,314		113,364		138,007
	Weighted shares of common stock outstanding – diluted		5,775,767		5,684,515		5,767,984		5,673,694
	Outstanding stock options totaling 251,000 for the three-month period ended September 30, 2014 and 255,650 for the three and nine-month periods ended September 30, 2013 were excluded from the net income per common share calculation because the shares would be anti-dilutive. There were no anti-dilutive options outstanding during the nine-months ended September 30, 2014.

Note_4_Goodwill_and_Intangible

Note 4 - Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	Note 4 – Goodwill and Intangible Assets
	The changes in the carrying amount of goodwill for the nine-month period ended September 30, 2014 were as follows:
		Package						Industrial Analyzers
		Testing			Permeation			& Other		Total
	Balance as of December 31, 2013	$	6,196,572		$	2,227,977		$	609,930	$	9,034,479
	Foreign currency translation		(443,512	)		(147,967	)		-		(591,479	)
	Balance as of September 30, 2014	$	5,753,060		$	2,080,010		$	609,930	$	8,443,000
	We test goodwill for impairment annually at the reporting unit level using a fair value approach. We will perform our annual impairment test for goodwill in the fourth quarter.
	Other intangible assets (all of which are being amortized except projects in process) are as follows:
		As of September 30, 2014
					Accumulated
		Cost			Amortization			Net
	Patents	$	1,684,874		$	(406,601	)	$	1,278,273
	Trademarks and trade names		3,827,361			(616,845	)		3,210,516
	Developed technology		7,139,760			(1,983,267	)		5,156,493
	Customer relationships		834,960			(231,933	)		603,027
	Internally developed software		949,792			(22,900	)		926,892
	Other intangibles		255,119			(88,616	)		166,503
		$	14,691,866		$	(3,350,162	)	$	11,341,704
		As of December 31, 2013
					Accumulated
		Cost			Amortization			Net
	Patents	$	1,624,590		$	(408,656	)	$	1,215,934
	Trademarks and trade names		4,121,170			(495,897	)		3,625,273
	Developed technology		7,730,550			(1,503,163	)		6,227,387
	Customer relationships		904,050			(175,787	)		728,263
	Internally developed software		716,800			-			716,800
	Other intangibles		245,118			(40,572	)		204,546
		$	15,342,278		$	(2,624,075	)	$	12,718,203
	Total amortization expense for the three-month periods ended September 30, 2014 and 2013 was $323,172 and $307,176, respectively and $963,805 and $889,480, respectively, for the nine-month periods ended September 30, 2014 and 2013. Projects in process are not amortized until the patent or trademark is granted by the regulatory agency or the asset is ready for use. Estimated amortization expense for the remainder of 2014 and each of the four succeeding fiscal years and thereafter based on the intangible assets as of September 30, 2014 is as follows:
		Estimated Expense
	2014	$	281,600
	2015		1,289,694
	2016		1,269,760
	2017		1,235,769
	2018		1,205,000
	2019 & Thereafter		5,313,357
		$	10,595,180

Note_5_Accumulated_Other_Compr

Note 5 - Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	Note 5 – Accumulated Other Comprehensive Income (Loss)
	Adjustments to accumulated other comprehensive income (loss) consist of the following:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Beginning balance	$	359,204		$	(1,033,751	)	$	613,025		$	(627,294	)
	Foreign currency translation adjustments		(2,106,847	)		1,058,066			(2,360,668	)		651,609
	Amounts reclassified to earnings		--			--			--			--
	Accumulated other comprehensive income (loss)	$	(1,747,643	)	$	24,315		$	(1,747,643	)	$	24,315

Note_6_Investment_in_Affiliate

Note 6 - Investment in Affiliated Company	9 Months Ended
	Sep. 30, 2014
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]	'
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	'
	Note 6 – Investment in Affiliated Company
	In January 2010, we acquired a minority equity ownership interest in Luxcel Biosciences Limited (Luxcel) based in Cork, Ireland. The investment of €2.5 million (approximately $3.6 million) amounted to a 16.9% equity interest in Luxcel. We have evaluated the cost versus equity method of accounting for its investment in Luxcel and determined that we do not have the ability to exercise significant influence over the operating and financial policies of Luxcel and, therefore, accounts for our investment on a cost basis. The investment in Luxcel is carried on our condensed consolidated balance sheets at the original purchase price, adjusted for currency fluctuations. We believe that it is not feasible to readily estimate the fair value of our investment in Luxcel. Information related to future cash flows of Luxcel is not readily available as the entity is a start-up research and development company and future cash flows are highly dependent on their ability to obtain additional funding, gain acceptance of its products in the marketplace, and obtain regulatory approvals.
	During 2013, we paid $200,000 for two license and distribution agreements with Luxcel which grants us access to proprietary technology on an exclusive basis for a period of four years. In addition, the terms of the distribution agreement allow us to contract for future services. These services are purchased through upfront payments tied to specific work orders and are refundable if the work is cancelled, excluding amounts incurred for work completed up to the cancellation date. At September 30, 2014, a prepaid expense of $219,000 was recognized on the Condensed Consolidated Balance Sheet as a result of our contracting for future services to be provided by Luxcel.
	As part of the relationship with Luxcel, we purchase sensors that accompany our instruments for sale to an end user and we are required to pay a royalty to Luxcel on the sale of such instruments.

Note_7_Warranty

Note 7 - Warranty	9 Months Ended
	Sep. 30, 2014
Product Warranties Disclosures [Abstract]	'
Product Warranty Disclosure [Text Block]	'
	Note 7 – Warranty
	We provide a warranty for most of our products ranging from ninety days to one year, and cover parts and labor for non-maintenance repairs at our locations. Operator abuse, improper use, alteration, damage resulting from accident, or failure to follow manufacturer’s directions are excluded from warranty coverage.
	Warranty expense is accrued at the time of sale based on historical claims experience. Warranty reserves are also accrued for special rework campaigns for known major product modifications. We also offer extended warranty service contracts for select products when the factory warranty period expires.
	Warranty provisions and claims for the three and nine-month periods ended September 30, 2014 and 2013 were as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Beginning balance	$	230,687		$	240,550		$	335,533		$	240,621
	Warranty provisions		111,868			134,327			156,855			300,827
	Warranty claims		(101,980	)		(133,559	)		(251,813	)		(300,130	)
	Ending balance	$	240,575		$	241,318		$	240,575		$	241,318

Note_8_Debt

Note 8 - Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 8 – Debt
	Notes payable consists of the following:
		September 30,		December 31,
		2014		2013
	Note payable to bank, with interest at 3.46%, payable	$	1,385,404	$	2,041,660
	in monthly principal installments of $72,917 plus interest
	through March 28, 2016, collateralized by all the assets of
	the Company except the outstanding stock of Dansensor.
	Seller financed note payable (Seller Note), with interest		940,846		1,914,941
	at 3.46%, payable in semi-annual payments of principal
	and interest totaling $891,000 beginning October 2, 2012
	through April 2, 2015, collateralized by 65% of the
	outstanding stock of Dansensor.
	Capital leases		34,095		47,926
	Total notes payable	$	2,360,345	$	4,004,527
	Less current portion of notes payable		1,819,312		2,697,678
	Total long-term notes payable	$	541,033	$	1,306,849
	In the U.S., we have a $6.0 million secured revolving line of credit with a maturity date of March 28, 2016. Interest is charged monthly at one-month LIBOR plus 1.75 basis points which totaled 2.00% at September 30, 2014 and December 31, 2013. The line of credit is secured by the assets of the Company with the exception of the outstanding stock of Dansensor, and there was $4,500,000 and $4,000,000 outstanding at September 30, 2014 and December 31, 2013, respectively. In Denmark, the Company has a DKK 10,000,000 (approximately $1.70 million) available line of credit of which no amount was outstanding as of September 30, 2014 and $264,000 was outstanding as of December 31, 2013. Outstanding borrowings on the Denmark line of credit are charged interest at 4.35% per year.
	We are subject to various financial and restrictive covenants in the bank Credit Agreement, including maintaining certain financial ratios and limits on incurring additional indebtedness, making capital and lease expenditures and making share repurchases. As of September 30, 2014, we were in compliance with these various covenants and expect to remain in compliance throughout 2014.
	The carrying value of the Seller Note is adjusted for foreign currency translation at each reporting period and the change in value is included in other expense in the condensed consolidated statements of income.
	As of September 30, 2014, the future minimum principal payments of the notes payable for the remainder of 2014 and each of the four succeeding fiscal years and thereafter are as follows:
	2014	$	1,064,199
	2015		988,182
	2016		305,222
	2017		2,742
		$	2,360,345

Note_9_Income_Taxes

Note 9 - Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 9 – Income Taxes
	Our provision for income tax expense was 29% and 25% of income before income taxes for the third quarters ended September 30, 2014 and 2013, respectively. The rate in the third quarter 2014 was lower than the statutory rate due primarily to the effect of foreign operations where tax rates tend to be lower as well as the domestic manufacturing deduction. The rate in the third quarter 2013 was lower than the statutory rate due primarily to certain discrete adjustments totaling $109,000 recorded during the quarter.
	For the nine-month period ended September 30, 2014, our income tax expense was 30% of income before income taxes compared to 20% for the same period of 2013. The rate for the first nine-months of 2014 was lower than the statutory rate due primarily to the effect of our foreign operations and the domestic manufacturing deduction. The rate for the first nine-months of 2013 was positively impacted by the tax law changes noted above as well as the domestic tax law change related to research and development credits which was effective in the first quarter 2013.
	As of September 30, 2014 and December 31, 2013, the liability for gross unrecognized tax benefits was $295,000 and $304,000, respectively. Changes in gross unrecognized tax benefits during the nine-months ended September 30, 2014 primarily consisted of a decrease for tax positions taken in the current year. It is expected that the amount of unrecognized tax benefits for positions which the we have identified will not materially change in the next twelve months.

Note_10_StockBased_Compensatio

Note 10 - Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 10 – Stock-Based Compensation
	As of September 30, 2014, we have reserved 151,639 shares of common stock for options and other stock-based incentive awards that are still available for grant under our 2006 stock incentive plan, and 684,325 shares for options that have been granted under either the 2006 stock incentive plan or the 1998 stock option plan but have not yet been exercised. We issue new shares of common stock upon exercise of stock options. There were options for an aggregate total of 146,400 shares granted in the first nine-months of 2014.
	Amounts recognized in the condensed consolidated financial statements related to stock-based compensation are as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Total cost of stock-based compensation	$	129,309		$	129,594		$	413,447		$	390,269
	Amount of income tax benefit recognized in earnings		(24,311	)		(14,590	)		(67,275	)		(58,393	)
	Amount charged against net income	$	104,998		$	115,004		$	346,172		$	331,876
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model (Black-Scholes). We use historical data to estimate the expected price volatility, expected option life and expected forfeiture rate. Our estimates are based on expected volatility for awards granted on daily historical trading data of our common stock for a period equivalent to the expected term of the award.
	The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option. We estimate the expected term consistent with historical exercise and cancellation activity of its previous share-based grants with a seven year contractual term. Forfeitures are based on historical experience. The dividend yield is calculated based upon the dividend payments made during the prior four quarters as a percent of the average stock price for that period.
	A summary of the option activity for the first nine-months of 2014 is as follows:
		Number of			Weighted			Weighted			Aggregate
		Shares			Average			Average			Intrinsic
					Exercise			Remaining			Value
					Price per			Contractual
					Share			Term
	Outstanding at December 31, 2013		622,300		$	12.34			3.7		$	2,174,673
	Options granted		146,400		$	15.86			6.3
	Options cancelled/expired		(16,950	)	$	15.34			--
	Options exercised		(67,425	)	$	10.09			--
	Outstanding at September 30, 2014		684,325		$	13.24			3.8		$	1,386,223
	Exercisable at September 30, 2014		526,600		$	12.61			3.3		$	1,348,418
	The total intrinsic value of options exercised was $68,433 and $10,133 during the three-month periods ended September 30, 2014 and 2013, respectively, and $404,373 and $183,421 during the nine-month periods ended September 30, 2014 and 2013, respectively.
	A summary of the status of our unvested option shares as of September 30, 2014 is as follows:
		Number of			Weighted
		Shares			Average
					Grant Date
					Fair Value
	Unvested at December 31, 2013		79,225		$	3.98
	Options granted		146,400		$	4.13
	Options cancelled		(15,400	)	$	3.98
	Options vested		(52,500	)	$	4.39
	Unvested at September 30, 2014		157,725		$	3.98
	As of September 30, 2014, there was $403,080 of total unrecognized compensation cost related to unvested stock-based compensation granted under our plans. That cost is expected to be recognized over a weighted-average period of 1.2 years. The total fair value of option shares vested during the three-month periods ended September 30, 2014 and 2013 was $76,799 and $71,756, respectively, and $230,475 and $215,269 during the nine-month periods ended September 30, 2014 and 2013, respectively.

Note_11_Derivative_Instrument

Note 11 - Derivative Instrument	9 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments and Hedging Activities Disclosure [Text Block]	'
	Note 11 – Derivative Instrument
	As of September 30, 2014, we had one foreign currency contract outstanding with a notional amount of 6.2 million Danish krone (DKK) or $1.0 million. The foreign currency contract was purchased to economically hedge the foreign currency fluctuation from the remeasurement of the third party seller financed note payable (Seller Note) which is denominated in DKK (Note 8). The term of the foreign currency contract, and its settlement dates, coincide with the maturity of the Seller Note which is April 2, 2015. The fair value of the contract resulted in an asset of approximately $11,000 at September 30, 2014, as compared to approximately $183,000 at December 31, 2013. The decrease in the fair value of the contract totaling approximately $79,000 for the three-month period ended September 30, 2014 and the decrease of $172,000 for the nine-month period ended September 30, 2014 were recognized in other expense in the condensed consolidated statements of income. Substantially all of this expense is offset by the re-measurement of the Seller Note.

Note_12_Fair_Value_Measurement

Note 12 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Note 12 – Fair Value Measurements
	We determine the fair market value of our derivative contract based on the fair value hierarchy, described below, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels within the fair value hierarchy that may be used to measure fair value:
	Level 1: Values based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities.
	Level 2: Values based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuation techniques for which all significant assumptions are observable in the market.
	Level 3: Values generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Company’s own estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques include use of option pricing models, discounted cash flow models and similar techniques.
	The following table provides information on those assets that are measured at fair value on a recurring basis:
				Fair Value
				Measurements
				at the end of
				the Reporting
				Period Using
	Assets:	Carrying		Significant Other
		value		Observable
				Inputs
				(Level 2)
	September 30, 2014:
	Foreign currency contract	$	10,859	$	10,859
	December 31, 2013:
	Foreign currency contract	$	183,137	$	183,137
	The fair value of the foreign currency contract is determined based on observable market transactions of spot currency rates and forward currency prices. The carrying values of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, revolving lines of credit and current maturities of notes payable approximate fair value due to their short-term maturity. The fair value of the long-term debt, measured as Level 2 financial instruments, is estimated based on anticipated interest rates which management believes would currently be available to us for similar issues of debt, taking into account our current credit risk of and other market factors. We believe the carrying value of the long-term debt approximates fair value.

Note_13_Business_Segments

Note 13 - Business Segments	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 13 – Business Segments
	We have four operating segments and three reportable segments, structured by differences in products and services, that are regularly reviewed by our chief operating decision maker to make decisions about allocating resources and assessing segment performance. The segment performance is evaluated at segment operating income which is defined as gross profit less selling, general and administrative expenses and research and development expenses. General corporate expenses, including costs associated with various support functions such as human resources, information technology, finance and accounting, and other general and administrative costs, are allocated to the reportable segments. Our four operating segments have been aggregated into three reportable segments based on the authoritative guidance. We aggregated our Other Products and Services operating segment into the Industrial Analyzer Products and Services segment based on minimal business activity and materiality.
	The Permeation segment includes instruments and services that measure the rate at which various gases and vapors permeate through a variety of materials. The Package Testing segment provides customers with the ability to assess package performance, shelf-life, package improvement, cost reduction, sustainability and product safety using Modified Atmosphere Packaging and other technologies. The Industrial Analyzers and Other segment includes advanced gas analysis and monitoring instrumentation used in applications such as oil and gas exploration, beverage and specialty gas analysis, industrial hygiene and safety, food safety and environmental air monitoring.
	The accounting policies of the reportable segments are the same as those described in Note 1 to the Consolidated Financial Statements found in our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2013. Intersegment sales for the three and nine-month periods ended September 30, 2014 and 2013 were insignificant.
	Financial information by reportable segment for the three and nine-month periods ended September 30, 2014 and 2013 is as follows:
		Three Months Ended					Nine Months Ended
		30-Sep-14					30-Sep-14
		Trade		Segment			Trade		Segment
		Revenue		Operating			Revenue		Operating
				Income					Income
	Permeation	$	5,729,373	$	1,228,580		$	16,621,767	$	2,923,453
	Package Testing		7,342,007		992,763			21,320,444		1,701,658
	Industrial Analyzers and Other		3,578,247		265,862			9,595,087		768,599
	Total	$	16,649,627	$	2,487,205		$	47,537,298	$	5,393,710
		Three Months Ended					Nine Months Ended
		30-Sep-13					30-Sep-13
		Trade		Segment			Trade		Segment
		Revenue		Operating			Revenue		Operating
				Income (Loss)					Income
	Permeation	$	5,596,470	$	1,325,605		$	15,550,031	$	2,630,193
	Package Testing		6,328,402		674,797			18,976,020		1,183,960
	Industrial Analyzers and Other		2,265,001		(85,434	)		7,799,015		265,383
	Total	$	14,189,873	$	1,914,968		$	42,325,066	$	4,079,536

Note_2_Inventories_Tables

Note 2 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		September 30,		December 31,
		2014		2013
	Finished products	$	1,730,912	$	1,638,997
	Work-in-process		2,645,502		1,934,493
	Raw materials		4,175,076		3,897,207
		$	8,551,490	$	7,470,697

Note_3_Net_Income_Per_Common_S1

Note 3 - Net Income Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Weighted Average Number of Shares [Table Text Block]	'
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Weighted shares of common stock outstanding – basic		5,667,810		5,548,201		5,654,620		5,535,687
	Dilutive impact of share-based awards		107,957		136,314		113,364		138,007
	Weighted shares of common stock outstanding – diluted		5,775,767		5,684,515		5,767,984		5,673,694

Note_4_Goodwill_and_Intangible1

Note 4 - Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill [Table Text Block]	'
		Package						Industrial Analyzers
		Testing			Permeation			& Other		Total
	Balance as of December 31, 2013	$	6,196,572		$	2,227,977		$	609,930	$	9,034,479
	Foreign currency translation		(443,512	)		(147,967	)		-		(591,479	)
	Balance as of September 30, 2014	$	5,753,060		$	2,080,010		$	609,930	$	8,443,000
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
		As of September 30, 2014
					Accumulated
		Cost			Amortization			Net
	Patents	$	1,684,874		$	(406,601	)	$	1,278,273
	Trademarks and trade names		3,827,361			(616,845	)		3,210,516
	Developed technology		7,139,760			(1,983,267	)		5,156,493
	Customer relationships		834,960			(231,933	)		603,027
	Internally developed software		949,792			(22,900	)		926,892
	Other intangibles		255,119			(88,616	)		166,503
		$	14,691,866		$	(3,350,162	)	$	11,341,704
		As of December 31, 2013
					Accumulated
		Cost			Amortization			Net
	Patents	$	1,624,590		$	(408,656	)	$	1,215,934
	Trademarks and trade names		4,121,170			(495,897	)		3,625,273
	Developed technology		7,730,550			(1,503,163	)		6,227,387
	Customer relationships		904,050			(175,787	)		728,263
	Internally developed software		716,800			-			716,800
	Other intangibles		245,118			(40,572	)		204,546
		$	15,342,278		$	(2,624,075	)	$	12,718,203
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
		Estimated Expense
	2014	$	281,600
	2015		1,289,694
	2016		1,269,760
	2017		1,235,769
	2018		1,205,000
	2019 & Thereafter		5,313,357
		$	10,595,180

Note_5_Accumulated_Other_Compr1

Note 5 - Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Beginning balance	$	359,204		$	(1,033,751	)	$	613,025		$	(627,294	)
	Foreign currency translation adjustments		(2,106,847	)		1,058,066			(2,360,668	)		651,609
	Amounts reclassified to earnings		--			--			--			--
	Accumulated other comprehensive income (loss)	$	(1,747,643	)	$	24,315		$	(1,747,643	)	$	24,315

Note_7_Warranty_Tables

Note 7 - Warranty (Tables)	9 Months Ended
	Sep. 30, 2014
Product Warranties Disclosures [Abstract]	'
Schedule of Product Warranty Liability [Table Text Block]	'
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Beginning balance	$	230,687		$	240,550		$	335,533		$	240,621
	Warranty provisions		111,868			134,327			156,855			300,827
	Warranty claims		(101,980	)		(133,559	)		(251,813	)		(300,130	)
	Ending balance	$	240,575		$	241,318		$	240,575		$	241,318

Note_8_Debt_Tables

Note 8 - Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt Instruments [Table Text Block]	'
		September 30,		December 31,
		2014		2013
	Note payable to bank, with interest at 3.46%, payable	$	1,385,404	$	2,041,660
	in monthly principal installments of $72,917 plus interest
	through March 28, 2016, collateralized by all the assets of
	the Company except the outstanding stock of Dansensor.
	Seller financed note payable (Seller Note), with interest		940,846		1,914,941
	at 3.46%, payable in semi-annual payments of principal
	and interest totaling $891,000 beginning October 2, 2012
	through April 2, 2015, collateralized by 65% of the
	outstanding stock of Dansensor.
	Capital leases		34,095		47,926
	Total notes payable	$	2,360,345	$	4,004,527
	Less current portion of notes payable		1,819,312		2,697,678
	Total long-term notes payable	$	541,033	$	1,306,849
Schedule of Maturities of Long Term Debt and Future Minimum Payments Under Capital Leases [Table Text Block]	'
	2014	$	1,064,199
	2015		988,182
	2016		305,222
	2017		2,742
		$	2,360,345

Note_10_StockBased_Compensatio1

Note 10 - Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	'
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Total cost of stock-based compensation	$	129,309		$	129,594		$	413,447		$	390,269
	Amount of income tax benefit recognized in earnings		(24,311	)		(14,590	)		(67,275	)		(58,393	)
	Amount charged against net income	$	104,998		$	115,004		$	346,172		$	331,876
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Number of			Weighted			Weighted			Aggregate
		Shares			Average			Average			Intrinsic
					Exercise			Remaining			Value
					Price per			Contractual
					Share			Term
	Outstanding at December 31, 2013		622,300		$	12.34			3.7		$	2,174,673
	Options granted		146,400		$	15.86			6.3
	Options cancelled/expired		(16,950	)	$	15.34			--
	Options exercised		(67,425	)	$	10.09			--
	Outstanding at September 30, 2014		684,325		$	13.24			3.8		$	1,386,223
	Exercisable at September 30, 2014		526,600		$	12.61			3.3		$	1,348,418
Schedule of Share-based Compensation Stock Options Unvested Activity [Table Text Block]	'
		Number of			Weighted
		Shares			Average
					Grant Date
					Fair Value
	Unvested at December 31, 2013		79,225		$	3.98
	Options granted		146,400		$	4.13
	Options cancelled		(15,400	)	$	3.98
	Options vested		(52,500	)	$	4.39
	Unvested at September 30, 2014		157,725		$	3.98

Note_12_Fair_Value_Measurement1

Note 12 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
				Fair Value
				Measurements
				at the end of
				the Reporting
				Period Using
	Assets:	Carrying		Significant Other
		value		Observable
				Inputs
				(Level 2)
	September 30, 2014:
	Foreign currency contract	$	10,859	$	10,859
	December 31, 2013:
	Foreign currency contract	$	183,137	$	183,137

Note_13_Business_Segments_Tabl

Note 13 - Business Segments (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
		Three Months Ended					Nine Months Ended
		30-Sep-14					30-Sep-14
		Trade		Segment			Trade		Segment
		Revenue		Operating			Revenue		Operating
				Income					Income
	Permeation	$	5,729,373	$	1,228,580		$	16,621,767	$	2,923,453
	Package Testing		7,342,007		992,763			21,320,444		1,701,658
	Industrial Analyzers and Other		3,578,247		265,862			9,595,087		768,599
	Total	$	16,649,627	$	2,487,205		$	47,537,298	$	5,393,710
		Three Months Ended					Nine Months Ended
		30-Sep-13					30-Sep-13
		Trade		Segment			Trade		Segment
		Revenue		Operating			Revenue		Operating
				Income (Loss)					Income
	Permeation	$	5,596,470	$	1,325,605		$	15,550,031	$	2,630,193
	Package Testing		6,328,402		674,797			18,976,020		1,183,960
	Industrial Analyzers and Other		2,265,001		(85,434	)		7,799,015		265,383
	Total	$	14,189,873	$	1,914,968		$	42,325,066	$	4,079,536

Note_2_Inventories_Details_Maj

Note 2 - Inventories (Details) - Major Components of Inventories (USD $)	Sep. 30, 2014	Dec. 31, 2013
Major Components of Inventories [Abstract]	'	'
Finished products	$1,730,912	$1,638,997
Work-in-process	2,645,502	1,934,493
Raw materials	4,175,076	3,897,207
	$8,551,490	$7,470,697

Note_3_Net_Income_Per_Common_S2

Note 3 - Net Income Per Common Share (Details) (Equity Option [Member])	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Equity Option [Member]	'	'	'	'
Note 3 - Net Income Per Common Share (Details) [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	251,000	255,650	0	255,650

Note_3_Net_Income_Per_Common_S3

Note 3 - Net Income Per Common Share (Details) - Reconciliation of the Denominators Used in the Computation of Net Income per Common Share	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Reconciliation of the Denominators Used in the Computation of Net Income per Common Share [Abstract]	'	'	'	'
Weighted shares of common stock outstanding b basic	5,667,810	5,548,201	5,654,620	5,535,687
Dilutive impact of share-based awards	107,957	136,314	113,364	138,007
Weighted shares of common stock outstanding b diluted	5,775,767	5,684,515	5,767,984	5,673,694

Note_4_Goodwill_and_Intangible2

Note 4 - Goodwill and Intangible Assets (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Amortization of Intangible Assets	$323,172	$307,176	$963,805	$889,480

Note_4_Goodwill_and_Intangible3

Note 4 - Goodwill and Intangible Assets (Details) - Changes in the Carrying Amount of Goodwill (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
		Package Testing Segment [Member]	Permeation Segment [Member]	Industrial Analyzers and Other Segment [Member]	Industrial Analyzers and Other Segment [Member]
Goodwill [Line Items]	'	'	'	'	'
Balance	$9,034,479	$6,196,572	$2,227,977	$609,930	$609,930
Foreign currency translation	-591,479	-443,512	-147,967	'	'
Balance	$8,443,000	$5,753,060	$2,080,010	$609,930	$609,930

Note_4_Goodwill_and_Intangible4

Note 4 - Goodwill and Intangible Assets (Details) - Other Intangible Assets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	$14,691,866	$15,342,278
Accumulated Amortization	-3,350,162	-2,624,075
Net	11,341,704	12,718,203
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	1,684,874	1,624,590
Accumulated Amortization	-406,601	-408,656
Net	1,278,273	1,215,934
Trademarks and Trade Names [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	3,827,361	4,121,170
Accumulated Amortization	-616,845	-495,897
Net	3,210,516	3,625,273
Developed Technology Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	7,139,760	7,730,550
Accumulated Amortization	-1,983,267	-1,503,163
Net	5,156,493	6,227,387
Customer Relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	834,960	904,050
Accumulated Amortization	-231,933	-175,787
Net	603,027	728,263
In Process Research and Development [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	949,792	716,800
Accumulated Amortization	-22,900	'
Net	926,892	716,800
Other Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	255,119	245,118
Accumulated Amortization	-88,616	-40,572
Net	$166,503	$204,546

Note_4_Goodwill_and_Intangible5

Note 4 - Goodwill and Intangible Assets (Details) - Amortization Expense Related to Intangible Assets (USD $)	Sep. 30, 2014
Amortization Expense Related to Intangible Assets [Abstract]	'
2014	$281,600
2015	1,289,694
2016	1,269,760
2017	1,235,769
2018	1,205,000
2019 & Thereafter	5,313,357
	$10,595,180

Note_5_Accumulated_Other_Compr2

Note 5 - Accumulated Other Comprehensive Income (Loss) (Details) - Adjustments to Accumulated Other Comprehensive Income (Loss) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Adjustments to Accumulated Other Comprehensive Income (Loss) [Abstract]	'	'	'	'
Accumulated other comprehensive income/(loss)	$359,204	($1,033,751)	$613,025	($627,294)
Foreign currency translation adjustments	-2,106,847	1,058,066	-2,360,668	651,609
Accumulated other comprehensive income/(loss)	($1,747,643)	$24,315	($1,747,643)	$24,315

Note_6_Investment_in_Affiliate1

Note 6 - Investment in Affiliated Company (Details) (Luxcel Biosciences Limited [Member])	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2014	Jan. 31, 2010	Jan. 31, 2010
	USD ($)	USD ($)	USD ($)	EUR (€)
Note 6 - Investment in Affiliated Company (Details) [Line Items]	'	'	'	'
Cost Method Investments	'	'	$3,600,000	€ 2,500,000
Cost Method Investments Ownership Percentage	'	'	16.90%	16.90%
Contractual Obligation Paid	200,000	'	'	'
Number Of Licenses	2	'	'	'
Term Of Licenses	'4 years	'	'	'
Prepaid Expense	'	$219,000	'	'

Note_7_Warranty_Details

Note 7 - Warranty (Details)	9 Months Ended
	Sep. 30, 2014
Product Warranties Disclosures [Abstract]	'
Product Warranty Period Low End of Range	'90 days
Product Warranty Period High End of Range	'1 year

Note_7_Warranty_Details_Warran

Note 7 - Warranty (Details) - Warranty Provisions and Claims (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Warranty Provisions and Claims [Abstract]	'	'	'	'
Balance	$230,687	$240,550	$335,533	$240,621
Warranty provisions	111,868	134,327	156,855	300,827
Warranty claims	-101,980	-133,559	-251,813	-300,130
Balance	$240,575	$241,318	$240,575	$241,318

Note_8_Debt_Details

Note 8 - Debt (Details)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
	Line of Credit [Member]	Line of Credit [Member]	Line of Credit [Member]	Dansensor [Member]	Dansensor [Member]	Dansensor [Member]
	London Interbank Offered Rate (LIBOR) [Member]	USD ($)	USD ($)	USD ($)	DKK	USD ($)
Note 8 - Debt (Details) [Line Items]	'	'	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	$6,000,000	'	$1,700,000	10,000,000	'
Debt Instrument, Description of Variable Rate Basis	'	'one-month LIBOR	'	'	'	'
Debt Instrument, Basis Spread on Variable Rate	0.02%	'	'	'	'	'
Line of Credit Facility, Interest Rate at Period End	'	2.00%	2.00%	'	'	'
Long-term Line of Credit	'	$4,500,000	$4,000,000	$0	'	$264,000
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	'	'	4.35%

Note_8_Debt_Details_LongTerm_N

Note 8 - Debt (Details) - Long-Term Notes Payable (USD $)	Sep. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Note payable to bank, with interest at 3.46%, payable in monthly principal installments of $72,917 plus interest through March 28, 2016, collateralized by all the assets of the Company except the outstanding stock of Dansensor.	$1,385,404	$2,041,660
Seller financed note payable (Seller Note), with interest at 3.46%, payable in semi-annual payments of principal and interest totaling $891,000 beginning October 2, 2012 through April 2, 2015, collateralized by 65% of the outstanding stock of Dansensor.	940,846	1,914,941
Capital leases	34,095	47,926
Total notes payable	2,360,345	4,004,527
Less current portion of notes payable	1,819,312	2,697,678
Total long-term notes payable	$541,033	$1,306,849

Note_8_Debt_Details_LongTerm_N1

Note 8 - Debt (Details) - Long-Term Notes Payable (Parentheticals) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Notes Payable to Banks [Member]	'	'
Debt Instrument [Line Items]	'	'
Interest	3.46%	3.46%
Monthly principal installments (in Dollars)	$72,917	$72,917
Seller Financed Secured Note Payable [Member]	'	'
Debt Instrument [Line Items]	'	'
Interest	3.46%	3.46%
Semi-annual principal and interest payments (in Dollars)	$891,000	$891,000
Collateralized by percent of the outstanding stock of Dansensor	65.00%	65.00%

Note_8_Debt_Details_Future_Min

Note 8 - Debt (Details) - Future Minimum Principal Payments of the Long-Term Notes Payable (USD $)	Sep. 30, 2014	Dec. 31, 2013
Note 8 - Debt (Details) - Future Minimum Principal Payments of the Long-Term Notes Payable [Line Items]	'	'
	$2,360,345	$4,004,527
Notes Payable [Member]	'	'
Note 8 - Debt (Details) - Future Minimum Principal Payments of the Long-Term Notes Payable [Line Items]	'	'
2014	1,064,199	'
2015	988,182	'
2016	305,222	'
2017	2,742	'
	$2,360,345	'

Note_9_Income_Taxes_Details

Note 9 - Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'	'	'	'	'
Effective Income Tax Rate Reconciliation, Percent	29.00%	25.00%	30.00%	20.00%	'
Prior Period Adjustment Income Tax Expense (Benefit) (in Dollars)	'	$109,000	'	$109,000	'
Unrecognized Tax Benefits (in Dollars)	$295,000	'	$295,000	'	$304,000

Note_10_StockBased_Compensatio2

Note 10 - Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2012
Note 10 - Stock-Based Compensation (Details) [Line Items]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	'	'	146,400	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$76,799	'	'	'	'
Employee Stock Option [Member] | Stock Incentive Plan 2006 and Stock Option Plan 1998 [Member]	'	'	'	'	'
Note 10 - Stock-Based Compensation (Details) [Line Items]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	684,325	'	684,325	'	'
Employee Stock Option [Member]	'	'	'	'	'
Note 10 - Stock-Based Compensation (Details) [Line Items]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	684,325	'	684,325	'	622,300
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	'	'	146,400	'	'
Share-based Compensation Arrangement by Share-based Payment Award Fair Value Assumptions Contractual Term	'	'	'7 years	'	'
Share-based Compensation Arrangement by Share-based Payment Award Fair Value Assumptions Number of Quarters Used In Calculation of Expected Dividend Rate	'	'	4	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	68,433	10,133	404,373	183,421	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	403,080	'	403,080	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'1 year 73 days	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	$71,756	$230,475	$215,269	'
Stock Incentive Plan 2006 [Member]	'	'	'	'	'
Note 10 - Stock-Based Compensation (Details) [Line Items]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	151,639	'	151,639	'	'

Note_10_StockBased_Compensatio3

Note 10 - Stock-Based Compensation (Details) - Stock-Based Compensation Expense (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock-Based Compensation Expense [Abstract]	'	'	'	'
Total cost of stock-based compensation	$129,309	$129,594	$413,447	$390,269
Amount of income tax benefit recognized in earnings	-24,311	-14,590	-67,275	-58,393
Amount charged against net income	$104,998	$115,004	$346,172	$331,876

Note_10_StockBased_Compensatio4

Note 10 - Stock-Based Compensation (Details) - Information Regarding the Company's Stock Option Plans (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Note 10 - Stock-Based Compensation (Details) - Information Regarding the Company's Stock Option Plans [Line Items]	'	'
Options granted	146,400	'
Employee Stock Option [Member]	'	'
Note 10 - Stock-Based Compensation (Details) - Information Regarding the Company's Stock Option Plans [Line Items]	'	'
Number of Shares	'	622,300
Weighted Average Exercise Price per Share	'	$12.34
Weighted Average Remaining Contractual Term	'3 years 292 days	'3 years 255 days
Aggregate Intrinsic Value	'	$2,174,673
Exercisable at September 30, 2014	526,600	'
Exercisable at September 30, 2014	$12.61	'
Exercisable at September 30, 2014	'3 years 109 days	'
Exercisable at September 30, 2014	1,348,418	'
Options granted	146,400	'
Options granted	$15.86	'
Options granted	'6 years 109 days	'
Options cancelled/expired	-16,950	'
Options cancelled/expired	$15.34	'
Options exercised	-67,425	'
Options exercised	$10.09	'
Number of Shares	684,325	'
Weighted Average Exercise Price per Share	$13.24	'
Weighted Average Remaining Contractual Term	'3 years 292 days	'3 years 255 days
Aggregate Intrinsic Value	$1,386,223	'

Note_10_StockBased_Compensatio5

Note 10 - Stock-Based Compensation (Details) - A Summary of the Status of the Company's Unvested Option Shares (USD $)	9 Months Ended
	Sep. 30, 2014
Note 10 - Stock-Based Compensation (Details) - A Summary of the Status of the Company's Unvested Option Shares [Line Items]	'
Options granted	146,400
Employee Stock Option [Member]	'
Note 10 - Stock-Based Compensation (Details) - A Summary of the Status of the Company's Unvested Option Shares [Line Items]	'
Unvested	79,225
Unvested	3.98
Options granted	146,400
Options granted	4.13
Options cancelled	-15,400
Options cancelled	3.98
Options vested	-52,500
Options vested	4.39
Unvested	157,725
Unvested	3.98

Note_11_Derivative_Instrument_

Note 11 - Derivative Instrument (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
	USD ($)	USD ($)	Designated as Hedging Instrument [Member]	Designated as Hedging Instrument [Member]	Designated as Hedging Instrument [Member]
			Foreign Exchange Contract [Member]	Foreign Exchange Contract [Member]	Foreign Exchange Contract [Member]
			USD ($)	DKK	USD ($)
Note 11 - Derivative Instrument (Details) [Line Items]	'	'	'	'	'
Number of Foreign Currency Derivatives Held	1	1	'	'	'
Derivative Asset, Notional Amount	'	'	$1,000,000	6,200,000	'
Derivative Asset, Fair Value, Gross Asset	'	'	11,000	'	183,000
Change in Unrealized Gain (Loss) on Foreign Currency Fair Value Hedging Instruments	($79,000)	($172,000)	'	'	'

Note_12_Fair_Value_Measurement2

Note 12 - Fair Value Measurements (Details) - Assets that are Measured at Fair Value on a Recurring Basis (Foreign Exchange Contract [Member], Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Inputs, Level 2 [Member]	'	'
Note 12 - Fair Value Measurements (Details) - Assets that are Measured at Fair Value on a Recurring Basis [Line Items]	'	'
Foreign currency contract	$10,859	$183,137
Reported Value Measurement [Member]	'	'
Note 12 - Fair Value Measurements (Details) - Assets that are Measured at Fair Value on a Recurring Basis [Line Items]	'	'
Foreign currency contract	$10,859	$183,137

Note_13_Business_Segments_Deta

Note 13 - Business Segments (Details)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Number of Operating Segments	4
Number of Reportable Segments	3

Note_13_Business_Segments_Deta1

Note 13 - Business Segments (Details) - Segment Information (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Trade Revenue	$16,649,627	$14,189,873	$47,537,298	$42,325,066
Segment Operating Income (Loss)	2,487,205	1,914,968	5,393,710	4,079,536
Permeation Segment [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Trade Revenue	5,729,373	5,596,470	16,621,767	15,550,031
Segment Operating Income (Loss)	1,228,580	1,325,605	2,923,453	2,630,193
Package Testing Segment [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Trade Revenue	7,342,007	6,328,402	21,320,444	18,976,020
Segment Operating Income (Loss)	992,763	674,797	1,701,658	1,183,960
Industrial Analyzers and Other Segment [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Trade Revenue	3,578,247	2,265,001	9,595,087	7,799,015
Segment Operating Income (Loss)	$265,862	($85,434)	$768,599	$265,383